Gilead Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Gilead Sciences
GILD Stock  USD 110.23  2.03  1.81%   
Gilead Sciences financial statements provide useful quarterly and yearly information to potential Gilead Sciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Gilead Sciences financial statements helps investors assess Gilead Sciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Gilead Sciences' valuation are summarized below:
Gross Profit
22.5 B
Profit Margin
0.0167
Market Capitalization
139.8 B
Enterprise Value Revenue
5.3531
Revenue
28.8 B
There are over one hundred nineteen available fundamental trends for Gilead Sciences, which can be analyzed over time and compared to other ratios. Investors should ensure to confirm all of Gilead Sciences' regular performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 108.5 B. The current year's Enterprise Value is expected to grow to about 106.5 B

Gilead Sciences Total Revenue

30.19 Billion

Check Gilead Sciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Gilead Sciences' main balance sheet or income statement drivers, such as Interest Expense of 549.9 M, Total Revenue of 30.2 B or Gross Profit of 23.6 B, as well as many indicators such as Price To Sales Ratio of 3.81, Dividend Yield of 0.0269 or PTB Ratio of 7.83. Gilead financial statements analysis is a perfect complement when working with Gilead Sciences Valuation or Volatility modules.
  
Check out the analysis of Gilead Sciences Correlation against competitors.
For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.

Gilead Sciences Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets61.9 B59 B48.9 B
Slightly volatile
Short and Long Term Debt Total3 B3.1 B17.3 B
Slightly volatile
Other Current Liabilities9 B8.5 B6.5 B
Slightly volatile
Total Current Liabilities12.6 B12 B8.7 B
Slightly volatile
Total Stockholder Equity20.3 B19.3 B16.9 B
Slightly volatile
Property Plant And Equipment Net5.7 B5.4 B3.4 B
Slightly volatile
Accounts Payable529.9 M833 M863.3 M
Slightly volatile
Cash10.5 B10 B7.8 B
Slightly volatile
Non Current Assets Total41.8 B39.8 B28.5 B
Slightly volatile
Cash And Short Term Investments7.6 B11.6 B14.3 B
Very volatile
Common Stock Shares Outstanding1.5 B1.3 B1.3 B
Very volatile
Liabilities And Stockholders Equity61.9 B59 B48.9 B
Slightly volatile
Non Current Liabilities Total29.1 B27.7 B23.3 B
Slightly volatile
Other Current Assets1.3 B1.5 B1.8 B
Pretty Stable
Other Stockholder Equity8.1 B7.7 B3.9 B
Slightly volatile
Total Liabilities41.7 B39.7 B32.1 B
Slightly volatile
Total Current Assets11.1 B19.2 B19.8 B
Pretty Stable
Short Term Debt1.9 B1.8 B1.4 B
Slightly volatile
Net Receivables2.5 B4.4 B3.6 B
Slightly volatile
Property Plant And Equipment Gross8.3 B7.9 B4.1 B
Slightly volatile
Short Term Investments2.6 B1.6 B3.6 B
Pretty Stable
Inventory1.3 B1.7 B1.7 B
Slightly volatile
Other Liabilities8.8 B8.4 B6.5 B
Slightly volatile
Other Assets1.1 M1.1 M1.7 B
Pretty Stable
Long Term Debt12.8 B24.9 B18.3 B
Slightly volatile
Common Stock Total Equity892.4 K1.1 M1 M
Pretty Stable
Capital Stock909 K1.1 M1 M
Pretty Stable
Common Stock909 K1.1 M1 M
Pretty Stable
Property Plant Equipment6.6 B6.3 B3.5 B
Slightly volatile
Good Will10 B9.6 B4.6 B
Slightly volatile
Long Term Debt Total19.7 B26.4 B19.4 B
Slightly volatile
Capital Surpluse2.7 B5 B3.4 B
Pretty Stable
Non Current Liabilities Other1.2 B1.3 B3.3 B
Slightly volatile
Deferred Long Term Asset Charges234.5 M462.3 M317.8 M
Slightly volatile
Intangible Assets17 B19.9 B16.4 B
Slightly volatile
Warrants1.7 M1.8 M6 M
Slightly volatile
Short and Long Term Debt3.3 B1.8 B3.2 B
Very volatile
Net Invested Capital38.8 B46 B50.3 B
Slightly volatile
Net Working Capital9 B7.2 B15 B
Slightly volatile

Gilead Sciences Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense549.9 M977 M720 M
Slightly volatile
Total Revenue30.2 B28.8 B22.1 B
Slightly volatile
Gross Profit23.6 B22.5 B18.1 B
Slightly volatile
Other Operating Expenses28.4 B27.1 B13.6 B
Slightly volatile
Total Operating Expenses21.9 B20.8 B9.2 B
Slightly volatile
Research Development6.2 B5.9 B4.2 B
Slightly volatile
Selling General Administrative6.4 B6.1 B3.7 B
Slightly volatile
Net Income Applicable To Common Shares4.9 B5.3 B5.8 B
Very volatile
Net Income From Continuing Ops455.1 M479 M5.5 B
Pretty Stable
Selling And Marketing Expenses650.2 M949.9 M563.3 M
Slightly volatile
Interest Income449.2 M281 M496.4 M
Slightly volatile
Non Recurring4.4 B4.2 B1.9 B
Slightly volatile
Reconciled Depreciation2.1 B2.8 B1.6 B
Slightly volatile

Gilead Sciences Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow3.5 B6.1 B6.8 B
Pretty Stable
Depreciation2.9 B2.8 B1.4 B
Slightly volatile
Capital Expenditures282.8 M523 M528.7 M
Slightly volatile
End Period Cash Flow10.5 B10 B7.8 B
Slightly volatile
Stock Based Compensation445.9 M835 M491 M
Slightly volatile
Dividends Paid3.5 B3.9 B3.2 B
Slightly volatile
Issuance Of Capital Stock319.9 M422 M291.7 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.814.005913.394
Slightly volatile
Dividend Yield0.02690.0340.0266
Slightly volatile
PTB Ratio7.835.95896.5327
Slightly volatile
Days Sales Outstanding53.356.107804
Slightly volatile
Book Value Per Share16.2115.433812.782
Slightly volatile
Stock Based Compensation To Revenue0.01980.0290.0217
Slightly volatile
Capex To Depreciation0.180.1890.4997
Slightly volatile
PB Ratio7.835.95896.5327
Slightly volatile
EV To Sales3.583.766613.2353
Slightly volatile
Inventory Turnover3.843.65562.7098
Slightly volatile
Days Of Inventory On Hand94.8699.848176
Slightly volatile
Sales General And Administrative To Revenue0.30.220.2071
Pretty Stable
Research And Ddevelopement To Revenue0.20.20540.5783
Slightly volatile
Capex To Revenue0.01730.01820.0379
Slightly volatile
Cash Per Share9.749.27678.5903
Slightly volatile
Payout Ratio8.578.16253.755
Slightly volatile
Income Quality23.6922.55839.7913
Slightly volatile
Current Ratio1.521.59722.6908
Slightly volatile
Receivables Turnover3.946.50545.3547
Slightly volatile
Graham Number18.4911.586730.2298
Pretty Stable
Shareholders Equity Per Share16.2815.501212.7948
Slightly volatile
Debt To Equity0.150.16090.8119
Pretty Stable
Capex Per Share0.440.41940.4129
Slightly volatile
Revenue Per Share24.2123.058516.7066
Slightly volatile
Interest Debt Per Share4.783.277512.3842
Slightly volatile
Debt To Assets0.05010.05270.2761
Pretty Stable
Operating Cycle148156952
Slightly volatile
Price Book Value Ratio7.835.95896.5327
Slightly volatile
Dividend Payout Ratio8.578.16253.755
Slightly volatile
Ebt Per Ebit0.680.41520.8628
Slightly volatile
Company Equity Multiplier1.623.0522.6368
Slightly volatile
Long Term Debt To Capitalization0.05960.06280.4192
Very volatile
Total Debt To Capitalization0.220.13860.3725
Pretty Stable
Debt Equity Ratio0.150.16090.8119
Pretty Stable
Quick Ratio1.381.45482.475
Slightly volatile
Net Income Per E B T0.920.69570.7376
Pretty Stable
Cash Ratio0.790.83231.3469
Slightly volatile
Cash Conversion Cycle102107132
Pretty Stable
Days Of Inventory Outstanding94.8699.848176
Slightly volatile
Days Of Sales Outstanding53.356.107804
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.120.95170.9573
Very volatile
Price To Book Ratio7.835.95896.5327
Slightly volatile
Fixed Asset Turnover5.015.3117.4308
Slightly volatile
Debt Ratio0.05010.05270.2761
Pretty Stable
Price Sales Ratio3.814.005913.394
Slightly volatile
Asset Turnover0.320.48740.4341
Very volatile
Gross Profit Margin1.060.78260.8632
Pretty Stable
Price Fair Value7.835.95896.5327
Slightly volatile

Gilead Sciences Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap108.5 B103.3 B99.1 B
Slightly volatile
Enterprise Value106.5 B101.5 B98.3 B
Slightly volatile

Gilead Fundamental Market Drivers

Forward Price Earnings14.1044
Cash And Short Term Investments11.6 B

Gilead Upcoming Events

6th of February 2024
Upcoming Quarterly Report
View
25th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Gilead Sciences Financial Statements

Gilead Sciences stakeholders use historical fundamental indicators, such as Gilead Sciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Gilead Sciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Gilead Sciences' assets and liabilities are reflected in the revenues and expenses on Gilead Sciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Gilead Sciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-2.1 B-2 B
Total Revenue28.8 B30.2 B
Cost Of Revenue6.3 B6.6 B
Stock Based Compensation To Revenue 0.03  0.02 
Sales General And Administrative To Revenue 0.22  0.30 
Research And Ddevelopement To Revenue 0.21  0.20 
Capex To Revenue 0.02  0.02 
Revenue Per Share 23.06  24.21 
Ebit Per Revenue 0.06  0.06 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce
When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:
How To Invest In Gilead
Details
Is Gilead Stock a good investment?
Details
What is Gilead Sciences' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.248
Dividend Share
3.08
Earnings Share
0.38
Revenue Per Share
23.059
Quarterly Revenue Growth
0.064
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY